Kyle LaHucik
@ky_lahucik
reporting on the $, people & startups in biotech land @Endpts | [email protected] | askin Qs, joggin 26.2 | š š· š | XC + Track coach | š³ļøāš
ID: 2682495362
https://endpts.com/author/kyle-lahucik/ 26-07-2014 14:33:08
5,5K Tweet
3,3K Followers
2,2K Following
Gileadās $4.3 billion acquisition of CymaBay earlier this year is shaping up: the FDA has approved the biotechās primary biliary cholangitis drug seladelpar, to be marketed as Livdelzi accessdata.fda.gov/drugsatfda_docā¦ Gilead bid against itself for the drugmaker endpts.com/gilead-bid-agaā¦
I tried to leave no stone unturned after a difficult day for Lykos and the employees there. Our Endpoints News interview with CEO Amy Emerson on what, exactly, is next: endpts.com/qa-lykos-just-ā¦
"Thereās actually a lot of leverage and control that the MAPS board has on Lykos." Meghana Keshavan with the first interview with Rick Doblin and its packed with details. statnews.com/2024/08/17/mdmā¦
3 yrs ago, the Biden Administration announced a $3.2B plan to build antivirals for Covid and whatever pandemic nature might throw at us next Most of the plan, I learned, was never enacted. And what was built ā 9 antiviral centers ā may soon be dismantled statnews.com/2024/08/26/nihā¦
We're heartbroken the great Amber Tong is leaving us, but excited to keep reading her bylineā¤ļø And... WE'RE HIRING! They're big shoes to fill, but we are on the hunt for a senior journalist to join our amazing team in London. Applications are open! ats.rippling.com/endpointsnews/ā¦
Every weekday morning starts with wisdom and guidance from Amber. Gonna miss having her as a coworker. Sheās helped drive Endpoints News for many years and makes our virtual newsroom buzz
CTA boss Dorval Carter spent more time traveling the world than visiting Chicago transit stations, his schedule shows. āļø Manny Ramos reports: buff.ly/3ABtm2E